Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial

Autor: Turan, Alparslan, Duncan, Andra, Leung, Steve, Karimi, Nika, Fang, Jonathan, Mao, Guangmei, Hargrave, Jennifer, Gillinov, Marc, Trombetta, Carlos, Ayad, Sabry, Hassan, Manal, Feider, Andrew, Howard-Quijano, Kimberly, Ruetzler, Kurt, Sessler, Daniel I, Bergese, Sergio, De Oliveira, Gildasio, Honar, Hooman, Niazi, Azfar, Elliott, Kavita, Hamadnalla, Hassan, Chodavarapu, Praneeta, Bajracharya, Gausan, Fitzgerald, Paul, Cuko, Evis, Akhtar, Zohaib, Lokhande, Chetan, Khan, Mohammad Zafeer, Khoshknabi, Dilara, Riter, Quinton, Hutcherson, Matthew, Yagar, Seyhan, Glosse, Logan, Saha, Partha, Raza, Syed
Zdroj: The Lancet; July 2020, Vol. 396 Issue: 10245 p177-185, 9p
Abstrakt: Atrial fibrillation and delirium are common consequences of cardiac surgery. Dexmedetomidine has unique properties as sedative agent and might reduce the risk of each complication. This study coprimarily aimed to establish whether dexmedetomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium.
Databáze: Supplemental Index